Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 14 January 2026 - 20 January 2026

Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

New York, January 20, 2026, 14:46 EST — During the regular session Pfizer (PFE) shares slipped 0.7% to $25.47 Tuesday afternoon, after GSK and Shionogi announced Pfizer will exit HIV-focused ViiV Healthcare in a $1.9 billion deal. Pfizer is set to get $1.88 billion for its 11.7% stake, with the deal expected to close in Q1 pending regulatory approval. That day, the stock fluctuated between $25.11 and $25.65. ViiV chair David Redfern called the move a way to “simplify the shareholder structure.” Pfizer has also cautioned investors that 2026 could be challenging, as COVID-19 product sales decline, pricing pressures mount,
20 January 2026
······
Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

New York, Jan 18, 2026, 10:37 EST — Market closed. Johnson & Johnson shares slipped 0.4% to $218.66 on Friday, the last session before U.S. markets shut for the Martin Luther King Jr. Day holiday. (Yahoo Finance) The stock heads into the week with investors leaning hard on earnings to justify valuations. “The most important thing right now is earnings,” said Chris Fasciano, chief market strategist at Commonwealth Financial Network. (Reuters) On Friday, U.S. stocks ended nearly flat in choppy trade, while the S&P 500 health care sector fell 0.8%, a bigger drop than the broader market. “We’re at the
18 January 2026
··········
Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

New York, January 18, 2026, 06:30 EST — Market closed Pfizer Inc (PFE) shares slipped 0.93% to $25.65 on Friday. Reuters reported that some drugmakers harbor quiet concerns over a White House-backed fast FDA review program, fearing it could increase legal risks if a rushed process overlooks safety problems. Pfizer has reportedly considered joining the initiative, according to Reuters. (Investing.com) U.S. stock markets will be closed Monday in observance of Martin Luther King Jr. Day, shortening the trading week and shifting the next session to Tuesday. This heightens the impact of any policy news released before the opening bell. (New
18 January 2026
·····
Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

NEW YORK, January 17, 2026, 14:16 EST — The market has closed. U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund (XLV) slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week. (Reuters) U.S. markets are closed Monday for Martin Luther King Jr. Day, giving healthcare investors an extended break before action resumes Tuesday. The sector has fallen behind despite earnings season picking
17 January 2026
··········
Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

New York, January 17, 2026, 07:32 EST — Market closed. Shares of Pfizer Inc (PFE) closed Friday down 0.9% at $25.65. Investors wrestled with a jumble of policy updates, regulatory filings, and a biotech IPO that dragged Pfizer’s name back into the paperwork spotlight. The next real hurdle for the stock arrives Tuesday. U.S. markets shut Monday for Martin Luther King Jr. Day, tightening the news flow and often making the session after the holiday a bit jittery. (NYSE) Pfizer CEO Albert Bourla expressed he was “seriously frustrated” following U.S. Health Secretary Robert F. Kennedy Jr.’s decision to roll back
17 January 2026
·····
Pfizer stock slips into long weekend as PFE investors line up earnings, dividend dates

Pfizer stock slips into long weekend as PFE investors line up earnings, dividend dates

New York, Jan 16, 2026, 20:21 EST — Market closed. Pfizer shares slipped 0.9% to close at $25.65 on Friday, just ahead of the U.S. market’s long weekend. Trading volume hit roughly 58 million shares. (MarketScreener) The tape will be silent Monday as U.S. exchanges shut down for Martin Luther King Jr. Day. Trading resumes Tuesday’s regular session. (New York Stock Exchange) Pfizer faces a packed schedule of catalysts in the coming weeks as it works to reverse a lengthy slide in its stock. In December, the company projected adjusted 2026 earnings of $2.80 to $3.00 per share on revenues
17 January 2026
·····
Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

New York, Jan 15, 2026, 13:24 EST — Regular session Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands. Why it matters now: vaccine makers face fresh political and demand challenges in the U.S. Sanofi CEO Paul Hudson warned of near-term “softness” in vaccine uptake, blaming “misinformation.” Pfizer CEO Albert Bourla expressed being “seriously frustrated,” labeling the trend as “political and antivax,” Reuters
15 January 2026
·····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

New York, Jan 15, 2026, 11:16 EST — Regular session. Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock. The stock has struggled to find a clear driver since Pfizer warned in December that 2026 would likely start “bumpy,” with lower COVID-related sales, price cuts tied to a U.S. government deal and key patent expirations looming. Loss of exclusivity is shorthand for patents ending, which can open the door to cheaper rivals. (Reuters) The political noise around vaccines is back in focus. Sanofi Chief Executive Paul
15 January 2026
·········
Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

New York, Jan 14, 2026, 19:09 EST — After-hours Shares of Pfizer (PFE.N) climbed Wednesday as investors focused on the company’s move into obesity treatments, now the key battleground in the pharmaceutical sector. The stock closed regular hours roughly 1.7% higher, settling at $25.58. After-hours trading remained subdued. The obesity story is crucial for Pfizer as it seeks to regain steady growth following the drop-off in COVID-era sales and faces looming patent expirations on major drugs that could invite cheaper competitors. Management has warned investors that the coming years may bring some volatility. Obesity stands out as one of the
15 January 2026
···
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

NEW YORK, Jan 14, 2026, 15:10 EST — Regular session Pfizer Inc shares climbed about 2% to $25.65 on Wednesday following CEO Albert Bourla’s remarks on the company’s push into the rapidly expanding cash-pay obesity drug market. “We are all in on obesity,” Bourla told reporters at the J.P. Morgan Healthcare Conference. Pfizer plans to launch 10 Phase 3 trials for its Metsera obesity compounds by the end of 2026, aiming to fuel future growth. The company still doesn’t expect revenue growth to return until 2029, as it navigates patent expirations and a slowdown in COVID-era sales. (Reuters) The shift
14 January 2026
····
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

NEW YORK, Jan 14, 2026, 11:47 EST — Regular session Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID. This move is crucial as investors demand evidence that Pfizer can develop fresh growth drivers ahead of a tough run of patent expirations. Obesity remains one of the few treatment areas attracting significant investment and rapid uptake, though competition is already fierce. At this week’s J.P. Morgan Healthcare Conference, Bourla laid out expectations for the year ahead as traders focus on whether pipeline
14 January 2026
·····
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

New York, Jan 14, 2026, 11:23 EST — Regular session Johnson & Johnson shares climbed 1.9% to $217.80 by late morning Wednesday, defying the SPDR S&P 500 ETF, which dipped roughly 1%. Healthcare outperformed the broader market. The Health Care Select Sector SPDR ETF edged up slightly, with Merck, Pfizer, and AbbVie each adding about 0.6%, 0.6%, and 0.5%, respectively. Shares are climbing again amid fresh legal developments ahead of next week’s earnings. Delaware’s Supreme Court on Monday threw out part of a September 2024 ruling over “milestone” payments tied to J&J’s $3.4 billion Auris Health acquisition in 2019. The
14 January 2026
········
1 2 3 4 5 … 10

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:49 AM EST CSL Faces Growth Uncertainty Amid Seqirus Spin-off Pause and Flu Vaccine Demand Drop February 7, 2026, 12:49 AM EST. CSL (ASX:CSL) confronts near-term challenges after delaying its Seqirus vaccine unit spin-off due to weaker U.S. flu vaccination uptake, impacting its fiscal 2026 growth outlook. Regulatory scrutiny in Europe over its Tavneos kidney therapy data, plus intensifying U.S. competition for its Vifor iron products, heighten concerns over product credibility and pricing pressure. Despite these headwinds, CSL's diversified portfolio in plasma, vaccines, and kidney therapies underpins its
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop